Myoseverin |
| Catalog No.GC15773 |
미세소관 결합 분자인 Myoseverina는 다핵 근관의 가역적 분열을 단핵 단편으로 유도합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 267402-71-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 16 nM
Myoseverin is a novel microtubule-binding molecule.
Microtubules are dynamic filamentous cytoskeletal proteins, which are composed of tubulin and are an critical therapeutic target in tumour cells. Drugs binding to microtubules have been the first-line standard of anticancer therapy for decades and until the advent of targeted therapy.
In vitro: Myoseverin was found to be able to induce the reversible fission of multinucleated myotubes into mononucleated fragments. In addition, cell proliferation and myotube fission promoted DNA synthesis after myoseverin removal and transfer of the cells to the fresh growth medium. Moreover, the biochemical analysis and transcriptional profiling showed that myoseverin alone did not reverse the processes of biochemical differentiation. However, myoseverin could affect the expression of various growth factor, extracellular matrix-remodeling, immunomodulatory, as well as stress response genes, which was consistent with the activation of pathways involved in tissue regeneration and wound healing [1]. Another study found that myoseverin-treated cardiac myocytes showed disruptions of the striated Z-bands with alpha-actinin and desmin. Similarly, active stathmin expression did not prevent the assembly of sarcomere. Moreover, the extent of MT destabilization caused by myoseverin and nocodazole were comparable [2].
In vivo: Currently, there is no animal in vivo data reported.
Clinical trial: Up to now, myoseverin is still in the preclinical development stage.
References:
[1] Rosania GR,Chang YT,Perez O,Sutherlin D,Dong H,Lockhart DJ,Schultz PG. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat Biotechnol.2000 Mar;18(3):304-8.
[2] Ng DC,Gebski BL,Grounds MD,Bogoyevitch MA. Myoseverin disrupts sarcomeric organization in myocytes: an effect independent of microtubule assembly inhibition. Cell Motil Cytoskeleton.2008 Jan;65(1):40-58.
| Cas No. | 267402-71-1 | SDF | |
| Chemical Name | (E)-9-isopropyl-N-(4-methoxybenzyl)-2-((4-methoxybenzyl)imino)-2,9-dihydro-1H-purin-6-amine | ||
| Canonical SMILES | CC(N1C=NC(C1=N/C2=N/CC3=CC=C(OC)C=C3)=C(N2)NCC4=CC=C(OC)C=C4)C | ||
| Formula | C24H28N6O2 | M.Wt | 432.52 |
| Solubility | DMF: 3.3 mg/ml,DMSO: 10 mg/ml,DMSO:PBS(pH 7.2) (1:2): 0.33 mg/ml,Ethanol: 0.11 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.312 mL | 11.5602 mL | 23.1203 mL |
| 5 mM | 0.4624 mL | 2.312 mL | 4.6241 mL |
| 10 mM | 0.2312 mL | 1.156 mL | 2.312 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *